Showing 2541-2550 of 3315 results for "".
- ViGeneron Announces First Patient Dosed in Phase 1b Trial of VG901 for the Intravitreal Treatment of RPhttps://modernod.com/news/vigeneron-announces-first-patient-dosed-in-phase-1b-trial-of-vg901-for-the-intravitreal-treatment-of-rp/2482224/ViGeneron announced that the first patient has been dosed in its phase Ib clinical trial evaluating intravitreal injection of VG901 to treat retinitis pigmentosa (RP) caused by mutations in the CNGA1 gene. This milestone marks an important advance as the company continues to leverage it
- Orbis Partners and Heidelberg Engineering Partner to Train Eye Care Professionals Around the Worldhttps://modernod.com/news/orbis-partners-with-heidelberg-engineering-to-train-eye-care-professionals-around-the-world/2482223/Orbis has announced a new partnership with Heidelberg Engineering, which will fund teaching opportunities and research focused on training eye care professionals around the world via Cybersight—Orbis’s award-winning telemedicine and e-learning platform. It will als
- Aviceda Therapeutics Announces Formation of European Clinical Advisory Boardhttps://modernod.com/news/aviceda-therapeutics-announces-formation-of-european-clinical-advisory-board/2482218/Aviceda Therapeutics announced the formation of its European Clinical Advisory Board (CAB) made up of internationally recognized thought leaders in retina. The CAB will provide strategic consultation on the company’s clinical development of its lead asset, AVD-104, for the treatment of geog
- New VR Solution Aims to Democratize Ophthalmic Surgical Traininghttps://modernod.com/news/new-vr-solution-aims-to-democratize-ophthalmic-surgical-training/2482216/At the ASCRS annual meeting in Boston, Orbis International and FundamentalVR launched a new immersive virtual reality (VR) training solution designed for use in low- and middle-income countries. The tool is built to support students and residents learning to perform surgery to trea
- RxSight Launches LAL+ and Features Multiple Doctor Presentations at ASCRShttps://modernod.com/news/rxsight-announces-commercial-launch-of-the-lal-and-features-multiple-doctor-presentations-at-ascrs/2482213/RxSight announced the commercial launch of its newest Light Adjustable Lens, the LAL+. The company now offers two lenses in the Light Adjustable Lens platform: the LAL and the Light Adjustable Lens+ (LAL+). The LAL+ has a modified aspheric anterior surface that creates a small cont
- Centricity Vision to Present at ASCRS and Eyeceleratorhttps://modernod.com/news/centricity-vision-to-present-at-ascrs-and-eyecelerator/2482203/Centricity Vision announced that it will present on its recently launched ZEPTOLink IOL Positioning System during the 2024 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting to be held April 5-8, 2024 in Boston. Additionally, Leonard Borrmann, the company’s newl
- Alcon to Highlight New Data at ASCRS Demonstrating Innovations Designed to Optimize Patient Outcomeshttps://modernod.com/news/alcon-to-highlight-new-data-at-ascrs-demonstrating-innovations-designed-to-optimize-patient-outcomes/2482199/Alcon will showcase approximately 100 company-supported and investigator-led data presentations demonstrating its latest innovative efforts aimed at optimizing patient outcomes at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, April 5-8, in Boston. In additio
- Staar Surgical Celebrates Milestone and Unveils New EVO ICL Data at ASCRShttps://modernod.com/news/staar-surgical-celebrates-milestone-and-unveils-new-evo-icl-data-at-ascrs/2482194/At the ASCRS annual meeting in Boston, April 5-8, 2024, Staar Surgical will be celebrating a commercial milestone: 3 million lenses sold. Staar will be showcasing the clinical, practice and innovation advantages of the EVO ICL through a series of posters, presentations and educational p
- Aldeyra Plans to Resubmit New Drug Application for Reproxalap in Dry Eye Diseasehttps://modernod.com/news/aldeyra-plans-to-resubmit-new-drug-application-for-reproxalap-in-dry-eye-disease/2482193/About 4 months after receiving a complete response letter (CRL) from the FDA, Aldeyra Therapeutics announced a clinical development plan intended to enable resubmission of a new drug application (NDA) of topical ocular 0.25% reproxalap, an investigational RASP modulator, for the treatment of dry
- Azura Ophthalmics to Present New Data Supporting the Potential of AZR-MD-001 to be the First Ophthalmic Keratolytic for Ocular Surface Diseaseshttps://modernod.com/news/azura-ophthalmics-to-present-new-data-supporting-the-potential-of-azr-md-001-to-be-the-first-ophthalmic-keratolytic-for-ocular-surface-diseases/2482185/Azura Ophthalmics announced multiple presentations highlighting positive efficacy and safety data from phase 2 studies of the company’s lead drug candidate, AZR-MD-001, in meibomian gland dysfunction (MGD). This includes new, long-term data at ASCRS of the company’s lead drug candidat